Cypralis is a private limited liability company and is currently owned by its founder shareholders. Our strategy is to raise finance from venture capital, pharma collaborations and non-dilutive funding sources in order to achieve the first clinical proofs of concept in acute indications where novel cyclophilin inhibitors may offer new breakthroughs for the treatment of serious hospital-based indications. Cypralis is also developing a pipeline of novel cyclophilin inhibitors for the treatment of chronic degenerative diseases caused by fibrosis and necrotic cell death.

Please contact us to explore opportunities for collaboration or investment.